Allergan deal with tribe could kill off IPR: Bryson
17-10-2017
A San Diego-based company has announced plans to sell a generic version of Allergan’s dry eye disease treatment Restasis (cyclosporine ophthalmic emulsion), just days after four patents covering the drug were invalidated.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Generics, Restasis, patent invalidation; Allergan; Saint Regis Mohawk Tribe; Judge William Bryson; dry eye disease; Imprimis Pharmaceuticals